Table 5.
Ibandronate long-term (5 year) bone mineral density (BMD) results after 60 months of treatment, relative (%) changes (mean values ± standard deviation with 95% confidence intervals [CIs])
| BMD and biochemical parameters | MOBILE (150 mg monthly) core baseline for the pooled-analysis mITT population (n=171) | 2 mg 2 monthly (n=362) | 3 mg 3 monthly (n=394) |
|---|---|---|---|
| Lumbar spine (L2–L4) BMD | 8.4±6.0 (7.5, 9.2), n=156 | 2.0±4.7 (1.5, 2.5), n=314 | 2.1±4.5 (1.6, 2.5), n=349 |
| Total hip BMD | 3.5±4.1 (2.8, 4.1), n=156 | −0.2±3.4 (−0.5, 0.2), n=314 | −0.3±4.0 (−0.7, 0.2), n=349 |
| Femoral neck BMD | 3.2±6.8 (2.1, 4.3), n=156 | 0.2±4.5 (−0.3, 0.7), n=314 | 0.8±5.8 (0.2, 1.4), n=349 |
| Trochanter BMD | 6.0±5.5 (5.1, 6.8), n=156 | 0.6±4.5 (0.1, 1.1), n=314 | 0.4±5.5 (−0.2, 1.0), n=349 |
| Serum CTXa | −56.6b (−64.7, −30.4), n=19 | 35.4 (5.9, 50.3), n=76 | 25.0 (9.2, 54.5), n=75 |
| Serum P1NPa | −61.3b (75.1, −56.4), n=19 | 29.1 (20.2, 40.1), n=76 | 24.1 (11.9, 41.9), n=75 |
Notes:
a
Median values with 95% CIs
b
per-protocol population.
Abbreviations: CTX, carboxy-terminal collagen crosslinks; mITT, modified intent to treat; MOBILE, Monthly Oral iBandronate In LadiEs; P1NP, procollagen type 1 N propeptide.